The release of free fatty acids (FFAs) from adipocytes (i.e. lipolysis) is increased in obesity and is a contributory factor to the development of insulin resistance. A recently identified adipokine, apelin, is up-regulated in states of obesity. Although apelin is secreted by adipocytes, its functions in them remain largely unknown. To determine whether apelin affects lipolysis, FFA, glycerol, and leptin levels, as well as abdominal adiposity, were measured at baseline and after reintroduction of exogenous apelin in apelin-null mice. To examine apelin's effects in vitro, isoproterenol-induced FFA/glycerol release, and hormone-sensitive lipase (HSL) and acetyl CoA carboxylase phosphorylation were investigated in 3T3-L1 cells and isolated wild-type adipocytes. Serum FFA, glycerol, and leptin concentrations, as well as abdominal adiposity, were significantly increased in apelin-null vs. wild-type mice; these changes were ameliorated in response to exogenous apelin. Apelin also reduced isoproterenol-induced FFA release in adipocytes isolated from wild-type but not APJ-null mice. In 3T3-L1 cells and isolated adipocytes, apelin attenuated isoproterenol-induced FFA/glycerol release. Apelin's inhibition was reversed by pertussis toxin, the G q inhibitor glycoprotein antagonist 2A, and the AMP-activated protein kinase inhibitors compound C and dorsomorphin. Apelin increased HSL phosphorylation at Ser-565 and also abrogated isoproterenol-induced HSL phosphorylation at Ser-563. Notably, apelin increased acetyl CoA carboxylase phosphorylation, suggesting AMPK activation. In conclusion, apelin negatively regulates lipolysis. Its actions may be mediated by pathways involving G q , G i , and AMP-activated protein kinase. (Endocrinology 152: 59 -68, 2011)
A
pelin is a novel peptide hormone that is the only known ligand for the previously orphaned angiotensin receptor-like G protein-coupled receptor APJ (1, 2) . Apelin has received attention in recent years due to the discovery of multiple unique effects in several tissues and organ systems, including the brain, heart, stomach, pancreas, and breast (3) . Given its sequence homology to the angiotensin type 1 receptor, APJ is believed to be coupled to the heterotrimeric G proteins G i (4) and G q (5) . Further downstream, apelin has also been shown to activate AMPactivated protein kinase (AMPK) and potentiate insulininduced Akt phosphorylation (6) . However, the relevance of these mechanisms, and their relationship to apelin's physiological effects, remains to be fully defined.
An important recent development has been the discovery that apelin regulates insulin sensitivity. Plasma apelin levels are associated with insulin resistance (7, 8) , and exogenous apelin administration is known to increase insulin sensitivity (6, 9, 10) . Interestingly, apelin has also been linked to obesity (7, 11) . Whereas early reports have highlighted a putative role for AMPK in mediating apelin's impact on these processes (6) , the underlying mechanisms governing apelin's metabolic effects are not well defined.
Within this framework, one process of potential interest is lipolysis [i.e. the adipocyte mediated breakdown of triglyceride stores to produce free fatty acids (FFAs)]. Although it serves an important physiological function in mobilizing fat stores in times of need, derangements in lipolysis have also been implicated in the pathogenesis of insulin resistance. Increased circulating FFA levels are observed in insulin-resistant individuals in the clinical setting (12, 13) . Additionally, the direct infusion of FFA results in decreased insulin-mediated glucose disposal (14 -16) . Finally, the reduction of FFA concentrations with the nicotinic acid analog acipimox has been shown to improve insulin sensitivity (14) . Although no direct evidence exists that it has an impact on lipolysis, it is notable that both apelin (7, 17) and APJ (18) are expressed by adipocytes. Moreover, lipolysis is modulated by other adipocyte-secreted substances, including leptin (19) , resistin (20) , and TNF-␣ (21) . These circumstantial observations suggest that apelin might have a demonstrable effect on lipolysis.
The intracellular lipolytic system has been well characterized. Although other relevant enzymes [e.g. adipocyte triglyceride lipase (ATGL), triglyceride hydrolases 1 and 2] have been identified, the best-studied effector responsible for triglyceride hydrolysis is hormone-sensitive lipase (HSL) (22) . HSL activity is regulated primarily by serine phosphorylation, both stimulatory[Ser-563, Ser-659, Ser-660 via cAMP/protein kinase A (PKA) (23) and Ser-600 via ERK (24) ] and inhibitory [Ser-565 via AMPK (25) ]. Also of importance are proteins present on the lipid droplet surface [most relevantly, perilipin (26) ], which regulate access to triglycerides by HSL (27) . However, as with lipolysis in general, it is uncertain whether apelin affects the expression and actions of these enzymes.
Given these questions, we have investigated apelin's effects on lipolysis. As model systems we used cultured 3T3-L1 adipocytes, isolated primary adipocytes, and two lines of mice deficient in apelin and APJ, respectively. We have determined that apelin is antilipolytic in our models. Moreover, we report that apelin alters HSL phosphorylation in these settings, suggesting a possible mechanism for its effects.
Materials and Methods

Animals
Generalized apelin-null (APKO) mice based on a 129Sv/J background, and generalized APJ-null (APJKO) mice based on a C57BL6/J background were produced by homologous recombination in embryonic stem cells. Detailed methodologies regarding construct, breeding, and husbandry of these two lines have been previously published (28) . As previously described, APKO mice are hyperinsulinemic and insulin resistant, without apparent differences in body weight vs. wild type (10, 28) . For all experiments involving APKO and APJKO mice, age-matched wild-type littermates were used as controls. Ten-week 129Sv/J mice used for ex vivo adipocyte phosphorylation studies (see Fig.  6 , C and D) were purchased from Charles River (Wilmington, MA). All animals were male.
Animals were maintained on a normal chow diet (Prolab RMH 3000; Purina-Mills, St. Louis, MO) containing 26% protein, 14% fat, and 60% carbohydrate by calorie count; given free access to tap water; and housed in a room with a 12-h light, 12-h dark cycle and an ambient temperature of 22 C. All protocols were approved by the Administrative Panel on Laboratory Animal Care at Stanford University School of Medicine and carried out in accordance with the guidelines of the American Association for the Accreditation of Laboratory Animal Care.
At euthanasia, animals were lethally anesthetized with isoflurane. Five hundred to 1000 l whole blood were obtained via ventricular cannulation and centrifuged at 13,200 rpm for 10 min. Two hundred to 250 l aliquots of plasma were then collected for FFA (NEFA kit; Wako Chemicals, Richmond, VA), glycerol (FG0100 free glycerol determination kit; Sigma-Aldrich, St. Louis, MO), and leptin (Procarta kit; Panomics, Santa Clara, CA) measurement. Epididymal adipose tissue was excised from each animal, weighed, and either (1) harvested for adipocyte isolation or (2) snap frozen in liquid nitrogen for downstream analysis.
Apelin infusion
Apelin infusion studies were performed on APKO mice aged 12 wk. After anesthetic induction with isoflurane, osmotic infusion pumps (Alzet 2002; Durect, Cupertino, CA) containing 2 mg/kg ⅐ d pyroglutamated apelin-13 (American Peptide, Sunnyvale, CA) or normal saline were implanted sc along the scruff of the neck. The dose was selected based on our prior experience (10). After 2 wk, selected groups were euthanized, and serum and adipose tissue were collected as described above. Animals undergoing computed tomography (CT) scanning (see below) were continued on the infusion for 2 more weeks and then euthanized. All animals were fasted for 6 h before euthanasia.
CT scanning
CT was performed on a GE eXplore RS MicroCT system (GE Healthcare Global Diagnostic Imaging, Waukesha, WI). The images were obtained over 200 degrees and reconstructed to 360 degrees with Parker software. Imaging parameters were: exposure 6.4 rads, scan time 7 min, field of view 4 cm, spatial resolution 97 m. Image gray scale was converted to Hounsfield units (HU) using a calibration phantom containing prospectively defined reference standards for air and bone.
Image analysis was performed with MicroView software (GE Healthcare). For each scan, a three-dimensional region of interest, defined as the fascial plane containing the peritoneal cavity, bounded superiorly by the dome of the liver and inferiorly by the penile shaft, was manually traced. An attenuation range for adipose tissue was determined for each scan by measuring the radiodensity of a sample volume within the epididymal fat. All voxels within the region of interest falling between Ϯ10 HU of the reference value (generally Ϫ250 to Ϫ200 HU) were then counted to determine intraabdominal adipose volume.
Western blotting of adipose tissue
Adipose tissue samples weighing approximately 100 mg were homogenized in lysis buffer (T-PER; Thermo Scientific, Rockford, IL) containing protease (Halt protease inhibitor; Thermo Scientific) and phosphatase (Phosphatase Inhibitor II; SigmaAldrich) inhibitors and centrifuged at 13,200 rpm for 15 min. Lysates were subjected to Western blotting with antibodies targeting Ser-79-phosphorylated acetyl CoA carboxylase (ACC), total ACC, Ser-563 phosphorylated, Ser-565 phosphorylated, and total HSL, perilipin, and ATGL (all from Cell Signaling Technology, Danvers, MA). Band intensity of phosphorylated antibodies normalized to the analogous total antibody was quantified with ImageJ software (National Institutes of Health, Bethesda, MD).
Adipocyte isolation and ex vivo lipolysis assay
Adipocyte isolation was performed as described previously (29) , with slight modifications. Briefly, at euthanasia, epididymal adipose tissue was excised from selected animals. Adipose samples were minced in Krebs-Ringer-bicarbonate-HEPES (KRBH) buffer (130 mM NaCl/5 mM KCl/1.3 mM CaCl 2 /1.3 mM MgSO 4 /25 mM HEPES, pH 7.4) containing 1% fatty acid-free BSA (Equitech-Bio, Kerrville, TX) at a ratio of 1.5 ml buffer for every 100 mg tissue. Adipose samples were digested with type I collagenase (1 mg/ml KRBH buffer; Worthington, Lakewood, NJ) for 60 min and then washed with KRBH buffer. One-hundred-microliter aliquots of adipocytes were then transferred to 12-well plates and incubated with isoproterenol (1 M) Ϯ pyroglutamated apelin-13 (1 M) for 2 h. FFA levels present in the medium were determined with a colorimetric kit (nonesterified fatty acid kit; Wako) and normalized to cell density. Selected 30-l aliquots exposed to apelin and/or isoproterenol were transferred to lysis buffer and subjected to Western blotting for phosphorylated and total HSL and ACC as described above.
Cell culture
Murine 3T3-L1 preadipocytes were obtained from American Type Culture Collection (Manassas, VA). Cells were grown at 37 C in 5% CO 2 in growth medium [DMEM (Life Technologies, Carlsbad, CA) plus 25 mM HEPES, 8 mg/liter D-biotin, 100 U/ml penicillin, 100 g/ml streptomycin, and 10% fetal bovine serum] and seeded in 12-well plates. Differentiation was induced as described previously (17) according to Student et al. (30) . For experiments, overnight-serum-starved, differentiated adipocytes were exposed to isoproterenol (Sigma; 1 M), pertussis toxin (PTX; EMD Biosciences; Gibbstown, NJ; 10 ng/ml), the AMPK inhibitors compound C (EMD Biosciences; 1 M) and dorsomorphin dihydrochloride (Tocris Bioscience; Ellisville, MO; 1 M), the G q inhibitor glycoprotein antagonist 2A (Gp2A; EMD Biosciences; 10 M), and/or pyroglutamated apelin-13 (10 Ϫ9 to 10 Ϫ5 M) at the indicated doses and times.
In vitro FFA and glycerol measurement
Differentiated 3T3-L1 adipocytes were incubated in DMEM with 1% fatty acid-free BSA and exposed to apelin and/or isoproterenol for 1 h Ϯ inhibitor pretreatment. FFA and glycerol content in the media was determined as delineated above. All experiments were carried out in duplicate.
Intracellular cAMP production
Intracellular cAMP production in apelin-and isoproterenolstimulated 3T3-L1 adipocytes was measured using a cAMP enzyme-linked immunoassay kit (Life Technologies). For full details please see the online Supplementary Methods, published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org.
Intracellular inositol 1,4,5-trisphosphate (IP 3 ) production
Intracellular IP 3 accumulation from apelin-stimulated 3T3-L1 adipocytes was measured using a fluorescence polarization assay (Discoverx, Fremont, CA). For full details please see the online Supplementary Methods.
Real-time quantitative PCR
For adipose tissue, samples weighing approximately 100 mg were homogenized in 1 mL Trizol (Life Technologies). For 3T3-L1 adipocytes, cells were lysed in 200 l Trizol. Tissue and cellular samples were subject to mRNA isolation, cDNA conversion, and real-time quantitative PCR as described previously (17) . Probe-primer sets (all from Life Technologies) for mouse HSL (Mm00495359_m1), ATGL (Mm00503040_m1), and perilipin (Mm00558672_m1) were purchased from Life Technologies.
Western blot analysis of 3T3-L1 cells
Differentiated 3T3-L1 adipocytes were treated with pyroglutamated apelin-13 and/or isoproterenol, harvested in lysis buffer, and subjected to Western blotting as above. Samples were probed with primary antibodies for phosphorylated and total forms of ACC and HSL as above. In addition, antibodies for Ser-133-phosphorylated cAMP response element binding protein (CREB) and total CREB (Cell Signaling) were used.
Statistics
For all experiments, comparisons between groups were made using two-way ANOVA (SPSS, Chicago, IL). All reported values are expressed as the means Ϯ SE of measurement. Prism 5.0 (GraphPad Software, La Jolla, CA) was used to produce graphs and curve fits. A P Ͻ 0.05 was considered statistically significant.
Results
APKO mice have increased FFA levels, glycerol levels, leptin levels, and adiposity
To assess whether chronic absence of apelin affected fatty acid handling, we investigated mice with generalized deficiency of apelin signaling (APKO mice) (28) . Compared with age-matched wild-type animals, APKO mice had significantly greater FFA and glycerol levels (Fig. 1) . Moreover, APKO mice had increased abdominal adiposity, as demonstrated by postmortem epididymal fat weight and CT scanning. Additionally, APKO mice had significantly increased leptin levels (7.92 Ϯ 5.12 vs. 6.43 Ϯ 0.29 ng/ml for APKO vs. WT, respectively; P Ͻ 0.05, n ϭ 5-7/ group). To determine whether exogenous apelin would Endocrinology, January 2011, 152(1):59 -68 endo.endojournals.orgreverse these changes, APKO mice were given an infusion of pyroglutamated apelin-13 (2 mg/kg ⅐ d). After 2 wk, FFA and glycerol levels were significantly decreased in apelin-treated APKO mice relative to a matched group treated with saline. Additionally, leptin levels were decreased, albeit not significantly (6.03 Ϯ 6.3 vs. 7.52 Ϯ 4.4 for apelin vs. saline, respectively; P ϭ 0.09, n ϭ 5/group). After 4 wk, abdominal adiposity and epididymal fat weight were also decreased by apelin. No differences in body weight between APKO and wild-type were seen at baseline or at any stage of the infusion. These data thus demonstrated that apelin is involved in the systemic regulation of FFA/glycerol levels.
APKO mice have altered HSL phosphorylation
We next measured whether apelin deletion had any measurable effect on HSL phosphorylation in the APKO mice. Adipose tissue from APKO and wild-type mice was subjected to Western blotting with antibodies for HSL phosphorylated at Ser-565 and Ser-563. Relative to wild-type, APKO mice had decreased Ser-565 phosphorylation, consistent with an inhibitory effect of endogenous apelin (Fig. 2) . Additionally, ACC phosphorylation was reduced in APKO mice, suggesting decreased activity of AMPK. Moreover, the apelin infusion resulted in reversal of these findings. Interestingly, APKOderived adipose tissue had significantly decreased Ser-563 phosphorylation, although exogenous apelin did not affect it. Notably, the mRNA and protein expressions of HSL, ATGL, and perilipin were not significantly altered between APKO and wild-type mice (Supplemental Fig. 1 ). Collectively, these data demonstrate that apelin is involved in HSL phosphorylation, supporting a possible mechanism for its putative regulation of FFA/glycerol levels.
Apelin's effects on FFA levels are mediated by its interaction with APJ Although our in vivo data spoke to a chronic effect of apelin deficiency, whether apelin possessed an acute impact on lipolysis remained unknown. Additionally, whereas APJ is the only known receptor for apelin, it remained possible that apelin might act by another pathway. To address these issues, we measured isoproterenol-induced lipolysis in adipocytes isolated from wild-type and APJ-null mice.
FIG. 1.
A, Serum FFA levels in wild-type mice, apelin-null mice, and apelin-null mice treated exogenously with either pyroglutamated apelin-13 (2 mg/kg ⅐ d) or saline for 2 wk. *, P Ͻ 0.05 vs. WT; †, P Ͻ 0.05 vs. saline-treated APKO mice. B, Serum-free glycerol levels in wildtype, apelin-null, and apelin-null mice treated with apelin or saline as denoted in A. *, P Ͻ 0.05 vs. wild type; †, P Ͻ 0.05 vs. saline-treated APKO mice. C, Representative transverse abdominal CT image from wild-type mouse. D, Representative abdominal CT image from APKO mouse. E, Abdominal fat content as measured by CT scanning, normalized to body weight. *, P Ͻ 0.01 vs. wild type. F, Abdominal fat content in APKO mice treated for 4 wk with pyroglutamated apelin-13 (2 mg/kg ⅐ d) or saline as measured by CT scanning, normalized to body weight. *, P Ͻ 0.05 vs. apelin group, baseline; †, P Ͻ 0.05 vs. saline group, end infusion. G, Epididymal adipose tissue weight in wild-type, APKO, and APKO mice treated with pyroglutamated apelin-13 or saline, normalized to body weight. *, P Ͻ 0.05 vs. wild type; †, P Ͻ 0.05 vs. saline-treated APKO mice. #, P Ͻ 0.05 vs. APKO mice at baseline. For baseline FFA/glycerol studies, n ϭ 4 -6 animals/group. For baseline CT studies, n ϭ 10 -15 animals per group. For infusion studies, n ϭ 4 -9 animals per group. For all experiments, results are expressed as the means Ϯ SE within each group. BW, Body weight; FW, epididymal adipose tissue weight; WT, wild type.
In wild-type adipocytes, isoproterenol induced a significant response in FFA release (Fig. 3) . Costimulation with pyroglutamated apelin-13 resulted in abrogation of this response. Notably, apelin had no such effect in the APJnull adipocytes. These findings confirm that apelin acutely modulates FFA release on a cellular level. Furthermore, APJ is involved in apelin's actions on FFA handling.
Apelin ameliorates isoproterenol-induced lipolysis in 3T3-L1 adipocytes
Given evidence of an acute apelin-mediated effect on lipolysis, we chose to investigate possible mechanisms for this phenomenon. We grew and differentiated 3T3-L1 adipocytes in culture for this purpose. Fully differentiated adipocytes were treated with isoproterenol (1 M) Ϯ pyroglutamated apelin-13 (1 M) for 1 h. In the absence of isoproterenol, apelin did not affect FFA or glycerol release from adipocytes. However, apelin inhibited isoproterenol-induced lipolysis in a dose-dependent manner (Fig. 4 , A and B; IC 50 78 nM for FFA and 107 nM for glycerol).
Using pharmacological inhibition studies, we found that apelin's reduction of FFA/glycerol release was blocked by pretreatment with the G q inhibitor Gp2A (10 M), the G i inhibitor PTX (10 ng/ml), and the AMPK inhibitors compound C (1 M) and dorsomorphin (1 M) (Fig. 4, C and  D) . Notably, in separate experiments, Gp2A, compound C, and dorsomorphin did not have a significant effect on FFA or glycerol release, either alone or in combination with isoproterenol (Supplemental Fig. 2 ). However, PTX did increase basal FFA/glycerol release significantly, albeit less than the combination of PTX, apelin, and isoproterenol. Taken together, these data suggest an acute apelin-mediated effect on FFA/glycerol release in cultured adipocytes. Moreover, apelin-mediated inhibition of isoproterenol-induced lipolysis may be dependent on G q , G i , and AMPK.
Apelin decreases intracellular cAMP accumulation and CREB phosphorylation and increases IP 3 production
To test further for evidence of apelin-mediated G i and G q activation, we measured cAMP and IP 3 accumulation in differentiated 3T3-L1 adipocytes exposed to apelin. A 60-min exposure to isoproterenol (1 M) was sufficient to significantly augment cAMP production (Fig. 5A) . However, this increase was inhibited when the adipocytes were costimulated with pyroglutamated apelin-13 (1 M), suggesting that apelin's antilipolytic actions may be mediated by its interaction with G i . To further support this contention, apelin was also found to decrease isoproterenol-mediated Ser-133 CREB phosphorylation (a PKA dependent process) in 3T3-L1 cells (Fig. 5B) (Fig. 5C) . Notably, this effect was comparable with that of angiotensin II (100 nM). Overall, these data lend further evidence of apelin-mediated G i and G q activation in 3T3-L1 adipocytes.
Apelin modulates HSL phosphorylation in vitro
To investigate the lipolytic apparatus more closely and to provide an in vitro correlate to our in vivo phosphorylation studies, we next assessed apelin's acute effects on HSL phosphorylation in cultured, differentiated 3T3-L1 adipocytes. 3T3-L1 cells were treated with isoproterenol (1 M) and/or pyroglutamated apelin-13 (1 M). As assessed by Western blotting, apelin alone did not significantly affect HSL phosphorylation at the Ser-563 residue (Fig. 6, A and B) . However, apelin did abrogate Ser-563 phosphorylation in response to isoproterenol, consistent with G i -mediated PKA inhibition. Interestingly, in the absence of isoproterenol, apelin also increased Ser-565 and ACC phosphorylation in a parallel fashion, suggesting AMPK activation distal to APJ. Notably, analogous to the data in APKO mice, apelin did not affect HSL, ATGL, or perilipin mRNA expression (data not shown).
Finally, the above experiments were repeated in adipocytes isolated from wild-type mice. As with the 3T3-L1 cells, pyroglutamated apelin-13 (1 M) increased Ser-565 and ACC phosphorylation and decreased isoproterenol-induced Ser-563 phosphorylation (Fig. 6,  C and D) . Combined with the results in 3T3-L1 cells, these findings suggest that apelin acutely inhibits HSL activation by reducing isoproterenol-mediated Ser-563 phosphorylation and also increasing Ser-565 phosphorylation.
Discussion
In this study we have determined that mice deficient in apelin signaling have increased FFA, glycerol, and leptin concentrations as well as abdominal adiposity. Moreover, restoration of apelin to APKO mice results in reversal of these changes. Additionally, we have found that apelin administration inhibits isoproterenol-induced lipolysis in cultured adipocytes. Finally, apelin may inhibit lipolysis by at least two mechanisms: attenuating PKA-mediated Ser-563 HSL phosphorylation and also increasing AMPK-mediated Ser-565 HSL phosphorylation. Furthermore, these mechanisms may be dependent on both G q -and G i -mediated pathways. To our knowledge, these data represent the first demonstration of an apelin-dependent effect on lipolysis. Taken together, our results support a framework whereby apelin inhibits lipolysis via both G q -AMPK-mediated Ser-565 phosphorylation and G i -PKA-mediated Ser-563 dephosphorylation.
Our data in isolated and cultured adipocytes indicate that apelin's effects on fatty acid release and HSL phosphorylation are acute. However, our in vivo results in APKO mice also suggest that apelin exerts an influence on a chronic basis as well. That the acute and chronic effects are approximately concordant suggests that apelin tolerance and/or resistance are not particularly significant, at least in our experimental settings. That said, because the apelin infusion lasted for only 2-4 wk, our data are inadequate to comment definitively on this matter. It should   FIG. 4 . A, Apelin-mediated inhibition of isoproterenol-induced FFA release. Differentiated 3T3-L1 adipocytes were costimulated with isoproterenol (1 M) and/or pyroglutamated apelin-13 at the indicated doses for 1 h. *, P Ͻ 0.05 vs. isoproterenol alone. B, Glycerol release in 3T3-L1 adipocytes treated as delineated in A. *, P Ͻ 0.05 vs. isoproterenol alone. C, FFA release in response to isoproterenol (1 M) stimulation in 3T3-L1 adipocytes with or without pyroglutamated apelin-13 (1 M) exposed to the indicated conditions and inhibitors for 1 h. *, P Ͻ 0.05 vs. control; #, P Ͻ 0.05 vs. isoproterenol alone; †, P Ͻ 0.05 vs. apelin and isoproterenol. D, Glycerol release in 3T3-L1 adipocytes treated as delineated in C. *, P Ͻ 0.05 vs. control; #, P Ͻ 0.05 vs. isoproterenol alone; †, P Ͻ 0.05 vs. apelin and isoproterenol. For dose response studies, n ϭ 7-12 separate experiments. For inhibition studies, n ϭ 6 -13 separate experiments. For all statistical comparisons, values are Ϯ SE of measurement. CC, Compound C; DD, dorsomorphin dihydrochloride; ISO, isoproterenol.
be noted that apelin resistance has been observed in failing myocardium (31, 32) ; we, however, are not aware of a similar observation in adipose tissue.
Consistent with its responsiveness to catecholamines, lipolysis is believed to serve a physiological role by recruiting a mobilizable energy source in times of stress. Additionally, lack of lipolysis is clearly detrimental, as evidenced in the clinical realm by the existence of syndromes resulting from deficiencies in the lipolytic apparatus (33) . Given these observations, it is reasonable to question whether apelin's inhibition of isoproterenol-induced lipolysis is helpful or harmful. That said, in situations with FFA excess, in which increased lipolysis is clearly detrimental (i.e. insulin resistance), it would seem that apelin might serve a beneficial role by inhibiting it.
In addition to lipolysis, our findings indicate that apelin may play an important role in regulating adiposity. Our results are consistent with those of Higuchi et al. (9) , who noted a decrease in mass of the epididymal, retroperitoneal, and mesenteric fat depots in mice given daily injections of apelin for 2 wk. Paradoxically, our findings appear to contradict apelin's putative inhibitory effect on FFA/glycerol release. That said, adiposity and lipolysis are not mutually exclusive phenomena; it is well appreciated that circulating FFA levels (13, 34) as well as basal rates of lipolysis (35, 36) are increased in states of obesity. It is thus possible that apelin's effects on adiposity and lipolysis are mediated by related but fundamentally separate processes.
Recent studies have indicated that apelin is up-regulated in states of insulin resistance (7) and augments insulin sensitivity directly (6, 9, 10) . Because insulin resistance is a condition of FFA excess, it is possible that apelin's intracellular effects on lipolysis and insulin sensitivity may have mechanistic similarities. One intermediate of potential interest is TNF-␣, which induces lipolysis via a nuclear factor-B (NF-B)-mediated mechanism (37) . Because of its pathogenetic role in insulin resistance (38) , it has been proposed that TNF-␣ in part underlies the increased FFA levels inherent in these circumstances. Apelin is up-regulated by TNF-␣ and has also been demonstrated to inhibit NF-B expression via an interaction between APJ and the type II angiotensin receptor (39) . One could thus hypothesize a negative feedback loop involving TNF-␣ and apelin, in which the latter would ameliorate the lipolytic effects of the former.
Based on our results in the APJKO animals, it seems clear that apelin's effects are a direct consequence of its binding to APJ. However, the signaling events downstream of APJ are less certain. As a G protein-coupled receptor, APJ is best known to associate with G i (4) . However, because it is well appreciated that G s stimulation leads to increased AMPK activity in adipocytes (40, 41) , it becomes difficult to reconcile apelin-mediated G i coupling with downstream activation of AMPK. Although PKA has been shown to inhibit AMPK by phosphorylating its ␣-Ser-485/491 residue (42) , this pathway has not been demonstrated in adipocytes, and as such it would be difficult to postulate an apelin-mediated disinhibition of AMPK in this manner.
To resolve this apparent paradox, a more plausible possibility would involve AMPK activation via G q . Although direct confirmation of an APJ-G q interaction is currently lacking, modeling based on helix-intracellular domain sequences and membrane topology using the Hidden Markov algorithm predicts coupling of APJ and G q with have shown that inhibition of phospholipase C, protein kinase C, or the Na ϩ /H ϩ and Na ϩ /Ca 2ϩ ion exchangers (all G q dependent entities) blocks the downstream actions of apelin. In our data set, the finding that apelin increases IP 3 accumulation provides more direct evidence of G q involvement. Additionally, the observation that Gp2A diminishes apelin's effects on isoproterenol-mediated lipolysis lends further support to apelin acting via G q .
Although it is well known that AMPK phosphorylates HSL at Ser-565 (44), the downstream effects of this action (and AMPK's overall regulation of lipolysis in general) are controversial. The original observation of an inhibitory effect by Garton et al. in 1989 (25) suggested that Ser-565 phosphorylation, although not overtly decreasing HSL activity, did prevent stimulatory HSL phosphorylation by PKA. These results have been borne out in subsequent research (45, 46) , including a recent study demonstrating that AMPK activation results in both increased Ser-565 phosphorylation and decreased Ser-563 phosphorylation, leading to a net reduction in lipolysis (47) . That said, several investigators have also reported a prolipolytic effect of AMPK (48, 49) . Although this discrepancy has yet to be resolved, given that apelin stimulates AMPK activity (6, 10) , our data are consistent with an inhibitory role for AMPK.
An apparent inconsistency with our results regarding apelin-mediated HSL phosphorylation concerns a paradoxical decrease in Ser-563 phosphorylation in APKO-derived adipose tissue relative to wild type. It is possible that an as-yet-unidentified systemic effect of apelin deficiency might underlie this finding. It is also plausible that in APKO mice, a comparative lack of (presumably APJ mediated) AMPK-induced Ser-563 phosphorylation (47) might be present, as it is with Ser-565. However, this explanation is less likely because exogenous apelin alone fails to affect Ser-563 phosphorylation in both APKO and 3T3-L1 adipocytes.
It should be cautioned that our in vitro mechanistic studies use pharmacological inhibition to dissect apelinmediated signaling events putatively leading to lipolysis. Indeed, consistent with our data, PTX has been shown to increase lipolysis by itself (50) . However, compound C, dorsomorphin, and Gp2A did not produce a measurable impact on FFA and glycerol release in 3T3-L1 cells, either alone or in combination with isoproterenol. Also, whereas the magnitude of PTX-induced FFA/glycerol release was significantly increased relative to control, it was also lower than that of the combination of apelin, isoproterenol, and PTX. In any event, our data would be strengthened by studies using alternative strategies (e.g. molecular inhibition) to suppress mediators of interest.
FIG. 6.
A, Representative Western blots for Ser-563-phosphorylated HSL in differentiated 3T3-L1 adipocyte lysates treated with pyroglutamated apelin-13 (1 M) with or without isoproterenol (1 M) for 1 h. Band intensities were normalized to total HSL. #, P Ͻ 0.05 vs. no apelin/no isoproterenol; , P Ͻ 0.05 vs. apelin/isoproterenol. B, Representative Western blots for Ser-565-phosphorylated HSL and Ser-79-phosphorylated ACC in 3T3-L1 lysates treated with pyroglutamated apelin-13 (1 M) for 1 h. Band intensities for each phosphorylated species were normalized to their respective total fractions. *, P Ͻ 0.05 vs. no apelin. C, Representative Western blots for Ser-563-phosphorylated hormone-sensitive lipase in isolated adipocytes (from wild type mice) treated with pyroglutamated apelin-13 (1 M) with or without isoproterenol (1 M) for 2 h. Band intensities were normalized to total HSL. #, P Ͻ 0.05 vs. no apelin/no isoproterenol; †, P Ͻ 0.05 vs. apelin/isoproterenol. D, Representative Western blots for Ser-565-phosphorylated HSL in isolated adipocytes treated with pyroglutamated apelin-13 (1 M) for 2 h. Band intensities for each phosphorylated species were normalized to their respective total fractions. *, P Ͻ 0.05 vs. no apelin. For all Western blots, each graph represents the average of three to five independent experiments. All indicated values are Ϯ SE of measurement. ISO, Isoproterenol; pACC, Ser-79-phosphorylated ACC; pHSL-563, Ser-563-phosphorylated HSL; pHSL-565, Ser-565-phosphorylated HSL.
In summary, we report the following findings. First, mice deficient in apelin signaling have increased circulating FFA and glycerol concentrations, increased adiposity, hyperleptinemia, and decreased Ser-565-HSL and ACC phosphorylation in adipocytes. These effects are reversed by exogenous apelin. Second, apelin attenuates isoproterenol-induced FFA and glycerol release in cultured adipocytes, decreases isoproterenol-induced HSL Ser-563 phosphorylation, and increases HSL Ser-565 phosphorylation. Finally, apelin's effects on FFA/glycerol release appear to be mediated by pathways involving the heterotrimeric G proteins G q and G i as well as AMPK. Although further elucidation of the underlying mechanism is required, our data highlight a novel action of apelin at the interface between fatty acid handling and insulin resistance.
